Antibodies

22 Feb 2017 Repatha® (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
21 Feb 2017 Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration
20 Feb 2017 New Data Demonstrate that Synaffix ADCs Significantly Expand the Therapeutic Index vs Cysteine-Engineered ADCs
18 Feb 2017 Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People with Locally Advanced or Metastatic Renal Cell Carcinoma
17 Feb 2017 New Data Shows STELARA® (ustekinumab) Maintained Clinical Response and Remission after Two Years of Treatment in Patients with Moderate to Severe Crohn’s Disease
17 Feb 2017 New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA® and REMICADE®a
17 Feb 2017 ArmaGen Reports Preliminary Evidence of Cognitive Improvement in Children with Hurler Syndrome (MPS I) Treated with AGT-181
16 Feb 2017 TRACON Pharmaceuticals Announces First Patient Dosed in Phase 3 TAPPAS Trial of TRC105 in Angiosarcoma
16 Feb 2017 XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa (HS)
16 Feb 2017 FDA approves new psoriasis drug
14 Feb 2017 Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
13 Feb 2017 MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20
13 Feb 2017 OncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer
11 Feb 2017 TRACON Pharmaceuticals Announces Top-line Results from NCI-Sponsored Phase 2 Trial of TRC105 in Recurrent Glioblastoma
08 Feb 2017 BioRestorative Therapies Receives FDA Clearance to Initiate Phase 2 Clinical Trial for the Treatment of Patients with Degenerative Disc Disease
08 Feb 2017 Lilly's Trulicity® (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes
06 Feb 2017 Ablynx submits a marketing authorisation application to the European Medicines Agency for caplacizumab, its anti-vWF nanobody, for the treatment of aTTP
06 Feb 2017 Innate Pharma announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab as a single agent in elderly patients with acute myeloid leukemia
03 Feb 2017 Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
03 Feb 2017 Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
02 Feb 2017 CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-072 Trial
01 Feb 2017 XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery
01 Feb 2017 European Commission Approves KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations
31 Jan 2017 Trillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial
27 Jan 2017 Amgen Receives Positive CHMP Opinion For ABP 501 (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top